PCVX logo

Vaxcyte, Inc. (PCVX) Cash From Financing

Annual CFF:

$2.45B+$1.81B(+282.69%)
December 31, 2024

Summary

  • As of today, PCVX annual cash from financing is $2.45 billion, with the most recent change of +$1.81 billion (+282.69%) on December 31, 2024.
  • During the last 3 years, PCVX annual cash from financing has risen by +$2.43 billion (+13658.75%).
  • PCVX annual cash from financing is now at all-time high.

Performance

PCVX Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXcash flow metrics

Quarterly CFF:

$2.52M+$1.76M(+231.75%)
June 30, 2025

Summary

  • As of today, PCVX quarterly cash from financing is $2.52 million, with the most recent change of +$1.76 million (+231.75%) on June 30, 2025.
  • Over the past year, PCVX quarterly cash from financing has dropped by -$107.85 million (-97.72%).
  • PCVX quarterly cash from financing is now -99.83% below its all-time high of $1.52 billion, reached on September 30, 2024.

Performance

PCVX Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXcash flow metrics

TTM CFF:

$1.52B-$107.85M(-6.61%)
June 30, 2025

Summary

  • As of today, PCVX TTM cash from financing is $1.52 billion, with the most recent change of -$107.85 million (-6.61%) on June 30, 2025.
  • Over the past year, PCVX TTM cash from financing has increased by +$543.37 million (+55.45%).
  • PCVX TTM cash from financing is now -37.79% below its all-time high of $2.45 billion, reached on December 31, 2024.

Performance

PCVX TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherPCVXcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

PCVX Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+282.7%-97.7%+55.5%
3Y3 Years+10000.0%-95.0%+759.4%
5Y5 Years+5790.5%-99.0%+266.4%

PCVX Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high>+9999.0%-99.8%+231.8%-37.8%+612.9%
5Y5-Yearat high>+9999.0%-99.8%+6894.4%-37.8%>+9999.0%
All-TimeAll-Timeat high>+9999.0%-99.8%+3370.1%-37.8%>+9999.0%

PCVX Cash From Financing History

DateAnnualQuarterlyTTM
Jun 2025
-
$2.52M(+231.8%)
$1.52B(-6.6%)
Mar 2025
-
$759.00K(-84.5%)
$1.63B(-33.4%)
Dec 2024
$2.45B(+282.7%)
$4.91M(-99.7%)
$2.45B(+0.1%)
Sep 2024
-
$1.52B(+1272.7%)
$2.45B(+149.7%)
Jun 2024
-
$110.37M(-86.5%)
$979.85M(-30.8%)
Mar 2024
-
$818.20M(>+9900.0%)
$1.42B(+121.4%)
Dec 2023
$639.81M(-25.7%)
$2.73M(-94.4%)
$639.81M(-50.5%)
Sep 2023
-
$48.55M(-91.1%)
$1.29B(+0.4%)
Jun 2023
-
$546.97M(+1216.0%)
$1.29B(+62.8%)
Mar 2023
-
$41.56M(-93.7%)
$792.09M(-8.1%)
Dec 2022
$861.55M
$656.63M(+1391.8%)
$861.55M(+303.2%)
Sep 2022
-
$44.02M(-11.8%)
$213.67M(+20.5%)
Jun 2022
-
$49.88M(-55.1%)
$177.25M(+38.1%)
DateAnnualQuarterlyTTM
Mar 2022
-
$111.02M(+1168.2%)
$128.33M(+621.1%)
Dec 2021
$17.80M(-95.3%)
$8.75M(+15.2%)
$17.80M(+85.4%)
Sep 2021
-
$7.60M(+694.9%)
$9.60M(+371.8%)
Jun 2021
-
$956.00K(+96.3%)
$2.03M(-99.2%)
Mar 2021
-
$487.00K(-12.3%)
$265.56M(-29.2%)
Dec 2020
$374.87M(+801.8%)
$555.00K(+1441.7%)
$374.87M(-9.8%)
Sep 2020
-
$36.00K(-100.0%)
$415.67M(-0.1%)
Jun 2020
-
$264.48M(+140.9%)
$416.00M(+174.7%)
Mar 2020
-
$109.80M(+165.5%)
$151.44M(+264.3%)
Dec 2019
$41.57M(-33.2%)
$41.35M(>+9900.0%)
$41.57M(>+9900.0%)
Sep 2019
-
$368.00K(+577.9%)
$215.00K(+240.5%)
Jun 2019
-
-$77.00K(-1.3%)
-$153.00K(-101.3%)
Mar 2019
-
-$76.00K
-$76.00K
Dec 2018
$62.19M
-
-

FAQ

  • What is Vaxcyte, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. annual cash from financing year-on-year change?
  • What is Vaxcyte, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. quarterly cash from financing year-on-year change?
  • What is Vaxcyte, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Vaxcyte, Inc.?
  • What is Vaxcyte, Inc. TTM cash from financing year-on-year change?

What is Vaxcyte, Inc. annual cash from financing?

The current annual cash from financing of PCVX is $2.45B

What is the all-time high annual cash from financing for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high annual cash from financing is $2.45B

What is Vaxcyte, Inc. annual cash from financing year-on-year change?

Over the past year, PCVX annual cash from financing has changed by +$1.81B (+282.69%)

What is Vaxcyte, Inc. quarterly cash from financing?

The current quarterly cash from financing of PCVX is $2.52M

What is the all-time high quarterly cash from financing for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high quarterly cash from financing is $1.52B

What is Vaxcyte, Inc. quarterly cash from financing year-on-year change?

Over the past year, PCVX quarterly cash from financing has changed by -$107.85M (-97.72%)

What is Vaxcyte, Inc. TTM cash from financing?

The current TTM cash from financing of PCVX is $1.52B

What is the all-time high TTM cash from financing for Vaxcyte, Inc.?

Vaxcyte, Inc. all-time high TTM cash from financing is $2.45B

What is Vaxcyte, Inc. TTM cash from financing year-on-year change?

Over the past year, PCVX TTM cash from financing has changed by +$543.37M (+55.45%)
On this page